Parkinson's Disease and Cannabis: What the Clinical Trials Actually Show

November 16, 2026 at 9:06 am|By nuggnotes Media
A ceramic cup on a dark wooden table, its surface disturbed by fine concentric ripples, lit by a single shaft of window light

Cannabis use is common among some people with Parkinson's, but the strongest available clinical evidence tells a different story: cannabinoids have not demonstrated meaningful benefits at the doses tested, and some risks are higher.

Two New Reviews Find No Significant Benefit

Two independent meta-analyses published in 2026 examined randomized controlled trials of cannabinoids for Parkinson's disease.

Fernandes and colleagues reviewed seven trials — spanning disease severity, motor function, non-motor symptoms and quality of life — and concluded that the evidence was "insufficient to establish clinically meaningful benefits."

Messak and colleagues identified 11 trials, six of which were eligible for meta-analysis. None of the pooled estimates showed significant improvement in Parkinson's disease severity, motor examination, motor activities of daily living or non-motor symptoms.

The Fernandes analysis also found significantly higher risks of confusion (4.44 times) and dizziness (2.78 times) in cannabinoid groups compared with placebo.

The Parkinson's scoreboard: pooled across the 2026 meta-analyses, cannabinoids showed no significant benefit over placebo on disease severity, motor examination, motor daily living, non-motor symptoms or quality of life, while confusion (risk ratio 4.44) and dizziness (risk ratio 2.78) were significantly more common. The two biggest trials — Liu 2024 (61 patients) and Kubota 2026 (101 patients, stopped early for futility) — were both negative

The Largest Trials Have Disappointed

Two of the newest and largest studies were negative.

A 2024 trial involving 61 patients found no significant motor improvement with CBD and THC compared with placebo. Sleep, cognition and daily-living measures favored placebo.

In 2026, a trial involving 101 participants, the largest Parkinson's cannabinoid trial to date, tested CBD/THC oil for Parkinson's-related pain. It found no significant pain benefit, and enrollment was stopped following an interim analysis that determined the treatment was unlikely to demonstrate sufficient benefit.

Where the Smaller Signals Fall Short

Some smaller studies have reported limited positive findings, but their designs matter.

A 2001 pilot involving just seven patients found that nabilone reduced levodopa-induced dyskinesia. A larger 2004 trial involving 19 patients found no such effect.

A 2020 nabilone study reported improvements in non-motor symptoms, but only people who had already responded to the drug during an earlier open-label phase entered the randomized portion.

Other findings are equally narrow: in a 24-patient crossover study, a single 300 mg CBD dose reduced anxiety-provoked tremor amplitude during a simulated public-speaking test. An early four-person case series reported improvements in REM sleep behavior disorder, but a later placebo-controlled trial involving 33 patients found no improvement in its primary outcomes.

Evidence for CBD and Parkinson's psychosis consists of one open-label study involving six patients.

Neuroprotection Has Not Been Demonstrated in People

Cannabinoids have shown neuroprotective effects in some preclinical Parkinson's models. However, these findings have not established a disease-modifying effect in people. No clinical evidence currently demonstrates that cannabinoids slow or reverse Parkinson's disease.

What Patients Should Know

A Parkinson's Foundation survey found that 24.5% of respondents had used cannabis in the previous six months. Among cannabis users, 65% had not received a recommendation to use cannabis from a licensed doctor or provider.

The American Academy of Neurology concluded that oral cannabis extract was probably ineffective for levodopa-induced dyskinesia. The Parkinson's Foundation does not endorse cannabis for Parkinson's symptoms.

No cannabis-based or cannabinoid medicine is approved specifically to treat Parkinson's disease by the FDA or European Medicines Agency.

Confusion and dizziness were significantly more common in cannabinoid-treated groups in the Fernandes meta-analysis. Drowsiness and orthostatic hypotension are additional safety concerns discussed in Parkinson's clinical literature. Potential interactions with Parkinson's medications warrant medical supervision, although a direct CBD–levodopa interaction has not been established.

The bottom line: Current randomized evidence does not show significant Parkinson's benefits from cannabinoids at the doses tested. That is different from proving they could never work, but the clinical evidence does not support presenting cannabis as an established Parkinson's treatment.

Sources

  1. Fernandes JVA et al. "Safety and efficacy of cannabinoid-based interventions in Parkinson's disease: A frequentist and bayesian meta-analysis of randomized controlled trials." Revue Neurologique, 2026. PMID: 42966680.
  2. Messak et al. Meta-analysis of cannabinoid RCTs in Parkinson's disease. Acta Neurologica Belgica, 2026. DOI: 10.1007/s13760-026-03082-0.
  3. Liu et al. CBD/THC extract randomized trial. Movement Disorders, 2024. PMID: 38487964.
  4. Kubota et al. Phase II CBD/THC oil trial for Parkinson's pain. Movement Disorders, 2026. PMID: 42563548.
  5. Sieradzan KA et al. Nabilone and dyskinesia pilot. Neurology, 2001. PMID: 11739835.
  6. Carroll CB et al. Cannabis extract crossover trial. Neurology, 2004. PMID: 15477546.
  7. Peball M et al. Nabilone non-motor trial (NMS-Nab). Annals of Neurology, 2020. DOI: 10.1002/ana.25864.
  8. de Faria SM et al. Single-dose CBD, anxiety and tremor. Journal of Psychopharmacology, 2020. PMID: 31909680.
  9. Chagas MCR et al. Cannabidiol and REM sleep behavior disorder case series. Journal of Clinical Pharmacy and Therapeutics, 2014. PMID: 24845114.
  10. de Almeida CMO et al. CBD for REM sleep behavior disorder trial. Movement Disorders, 2021. PMID: 33754375.
  11. Zuardi AW et al. CBD and Parkinson's psychosis pilot. Journal of Psychopharmacology, 2009. PMID: 18801821.
  12. Feeney MP et al. Parkinson's Foundation cannabis use survey. npj Parkinson's Disease, 2021. DOI: 10.1038/s41531-021-00165-y.
  13. Koppel BS et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology (American Academy of Neurology), 2014. PMID: 24778283.
  14. García-Arencibia M et al. Cannabinoids in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Research, 2007. DOI: 10.1016/j.brainres.2006.11.063.
  15. "Advice to People with Parkinson's in My Clinic: Cannabis." Journal of Parkinson's Disease, 2024. DOI: 10.3233/JPD-230358.
  16. Parkinson's Foundation. Statement on cannabis and Parkinson's disease, 2020.

0 comments

Leave a comment